Equities analysts forecast that Evoke Pharma Inc (NASDAQ:EVOK) will post earnings per share of ($0.06) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Evoke Pharma’s earnings. Evoke Pharma posted earnings of ($0.10) per share in the same quarter last year, which would suggest a positive year over year growth rate of 40%. The business is expected to issue its next earnings results on Wednesday, March 4th.
According to Zacks, analysts expect that Evoke Pharma will report full-year earnings of ($0.31) per share for the current financial year. For the next fiscal year, analysts forecast that the firm will post earnings of ($0.19) per share. Zacks’ EPS averages are an average based on a survey of sell-side research firms that follow Evoke Pharma.
Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.09) by $0.02.
EVOK stock traded down $0.02 during trading on Friday, hitting $1.57. The company had a trading volume of 6,312 shares, compared to its average volume of 557,609. The firm has a 50-day moving average price of $1.11 and a 200-day moving average price of $0.90. Evoke Pharma has a 12 month low of $0.50 and a 12 month high of $3.26. The stock has a market cap of $38.46 million, a price-to-earnings ratio of -3.41 and a beta of 1.86.
An institutional investor recently bought a new position in Evoke Pharma stock. Marshall Wace LLP acquired a new stake in Evoke Pharma Inc (NASDAQ:EVOK) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 92,406 shares of the specialty pharmaceutical company’s stock, valued at approximately $139,000. Marshall Wace LLP owned approximately 0.40% of Evoke Pharma at the end of the most recent reporting period. 6.57% of the stock is owned by institutional investors.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray, which is completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Further Reading: How to invest in a bear market
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.